New bladder cancer drug delivered directly into bladder shows early promise
NCT ID NCT05014139
First seen Nov 20, 2025 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This early-phase trial tested enfortumab vedotin, a drug placed directly into the bladder via a catheter, in 37 people with a type of bladder cancer that did not respond to standard BCG therapy. The main goals were to check safety and side effects, and to see if the drug could help control the cancer. The study was terminated early, so full results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URINARY BLADDER NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Erlanger Oncology and Hematology
Chattanooga, Tennessee, 37403, United States
-
Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington
Seattle, Washington, 98195, United States
-
James Cancer Hospital / Ohio State University
Columbus, Ohio, 43221, United States
-
Johns Hopkins Medical Center
Baltimore, Maryland, 21287, United States
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Markey Cancer Center / University of Kentucky
Lexington, Kentucky, 40508, United States
-
Mayo Clinic
Scottsdale, Arizona, 85259, United States
-
Northwestern University-Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
Oregon Health and Science University
Portland, Oregon, 98682, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, 19107, United States
-
Site CA11001
Toronto, Ontario, M5G 2C1, Canada
-
Site DE49001
Göttingen, 37075, Germany
-
Site DE49002
Tübingen, 72076, Germany
-
Site ES34001
Barcelona, 08025, Spain
-
Site ES34002
Madrid, 28041, Spain
-
Site ES34003
Barcelona, 08036, Spain
-
Site ES34004
Barcelona, 08035, Spain
-
Site FR33001
Paris, 75013, France
-
Site FR33002
Lyon, 69003, France
-
Site FR33003
Rennes, 35000, France
-
Site UK44002
London, EC1A 7BE, United Kingdom
-
Stanford Health Care
Stanford, California, 94305, United States
-
UCLA Department of Medicine - Hematology & Oncology
Los Angeles, California, 90095, United States
-
University of California at San Francisco
San Francisco, California, 94134, United States
-
University of California, Irvine
Orange, California, 92868, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
Urology San Antonio
San Antonio, Texas, 78229, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enfortumab vedotin (PADCEV)
What this could lead to
If it works, this could offer a new treatment option for people with bladder cancer that hasn't responded to standard therapy, potentially avoiding the need for bladder removal.
What could go wrong
This is a very early (Phase 1) trial that was terminated early, so results are limited. The drug may cause side effects and may not effectively control the cancer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.